Canadian guidelines for economic evaluation of pharmaceuticals

PharmacoEconomics

Volumn 9, Issue 6, 1996, Pages 535-559

  Torrance, George W ^a,b   Blaker, David ^c   Detsky, Allan ^d   Kennedy, Wendy ^e   Schubert, Francois ^f,g   Menon, Devidas ^h   Tugwell, Peter ⁱ   Konchak, Richard ^j   Hubbard, Eleanor ^k   Firestone, Theresa ^l  

^a MCMASTER UNIVERSITY   (Canada)

^b CENTRE FOR EVALUATION OF MEDICINES   (Canada)

^c HEALTH CANADA   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f GLAXOSMITHKLINE   (United States)

^g Pharmaceutical Manufacturers A   (Canada)

^h Can Coord Off Hlth Technol A   (Canada)

ⁱ UNIVERSITY OF OTTAWA   (Canada)

^j Patented Med Prices Review Board   (Canada)

^k Nova Scotia Department of Health   (Canada)

^l ONTARIO MINISTRY OF HEALTH AND LONG TERM CARE   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANADA; DECISION MAKING; HEALTH CARE; METHODOLOGY; PHARMACOECONOMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL;

EID: 9344259132     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199609060-00008     Document Type: Article

References (59)

1. Australian Commonwealth Department of Human Services and Health. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee: including major submissions involving economic analyses. Canberra: Australian Government Pubishing Service, 1995
2. Schubert F. Canadian collaborative workshop on pharmacoeconomics. Princeton (NJ): Excerpta Medica, Inc., 1993
3. Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Guidelines for economic evaluation of pharmaceuticals. 1st ed. Ottawa: CCOHTA, 1994
4. Weinstein MC. Principles of cost-effective resource allocation in health care organizations. Int J Technol Assess Health Care 1990; 6 (1): 93-103
5. Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 1987
6. Detsky AS, Naglie IG. A clinician's guide to cost-effectiveness analysis. Ann Intern Med 1990; 113 (2): 147-54
7. Bootman JL, Townsend RJ, McGhan WF, editors. Principles of pharmacoeconomics. Cincinnati: Harvey Whitney Books Company, 1991
8. Drummond MF, Torrance GW, Mason J. Cost-effectiveness league tables: more harm than good? Soc Sci Med 1993; 37 (1): 33-40
9. Miller GA. The magical number seven plus or minus two: some limits on our capacity to process information. Psychol Rev 1956; 63 (2): 81-97
10. Johannesson M, Jönsson B. Economic evaluation in health care: is there a role for cost-benefit analysis? Health Policy 1991; 17 (1): 1-23
11. Winston WL. Operations research: applications and algorithms. Boston: PWS-Kent Publishing Co., 1991
12. Culyer AJ. The normative economics of health care finance and provision. Oxford Rev Econ Policy 1989; 5 (1): 34-58
13. Culyer AJ. Commodities, characteristics of commodities, characteristics of people, utilities and the quality of life. In: Baldwin S, Godfrey C, Propper C, editors. Quality of life: perspectives and policies. London: Routledge, 1989; 9-27
14. Garber AM, Phelps CE. Economic foundations of cost-ef fectiveness analysis. NBER Working Paper No. 4164. Cambridge (MA): National Bureau of Economic Research, 1992
15. Tugwell P, Bennett K, Sackett D. The measurement iterative loop: a framework for the critical appraisal of need, benefits and costs of health interventions. J Chronic Dis 1985; 38 (4): 339-51
16. Torrance GW, Feeny D. Utilities and quality-adjusted life years. Int J Technol Assess Health Care 1989; 5 (4): 559-75
17. Mehrez A, Gafni A. Quality-adjusted life years, utility theory, and healthy-years equivalents. Med Decis Making 1989; 9 (2): 142-9
18. Mehrez A, Gafni A. The healthy-years equivalents: how to measure them using the standard gamble approach. Med Decis Making 1991; 11 (2): 140-6
19. Mehrez, A. Gafni A. Preference based outcome measures for economic evaluation of drug interventions: quality adjusted life years (QALYs) versus healthy years equivalents (HYEs). PharmacoEconomics 1992; 1 (5): 338-45
20. Buckingham K. A note on HYE (Healthy Years Equivalent). J Health Econ 1993; 12 (3): 301-9
21. Culyer AJ, Wagstaff A. QALYs (quality-adjusted life-years) versus HYEs (healthy years equivalents). J Health Econ 1993; 12 (3): 311-23
22. Gafni A, Birch S, Mehrez A. Economics, health and health economics: HYEs (healthy-years equivalent) versus QALYs (quality-adjusted life-year). J Health Econ 1993; 12 (3): 325-39
23. Fryback DG. QALYs, HYEs, and the loss of innocence [editorial]. Med Decis Making 1993; 13 (4): 271-2
24. Johannesson M, Pliskin JS, Weinstein MC. Are healthy-year equivalents an improvement over quality-adjusted life years? Med Decis Making 1993; 13 (4): 281-6
25. Mehrez A, Gafni A. Healthy-years equivalents versus quality-adjusted life years: in pursuit of progress. Med Decis Making 1993; 13 (4): 287-92
26. Von Neumann J, Morgenstern O. Theory of games and economic behaviour. Princeton (NJ): Princeton University Press, 1953
27. Patrick DL, Erickson P. Health status and health policy: quality of life in health care evaluation and resource allocation. New York: Oxford University Press, 1993
28. Feeny DH, Torrance GW, Goldsmith CH, et al. A multi-attribute approach to population health status. Proceedings of the Social Statistics Section. Session IX: measuring health status: survey-based approaches. Alexandria (VA): American Statistical Association, 1994: 161-6
29. Furlong W, Torrance GW, Feeny D, et al. McMaster health utilities index of health-related quality of life [abstract]. Qual Life Res 1994; 3: 76-7
30. Kaplan RM, Anderson JP. A general health policy model: update and applications. Health Serv Res 1988; 23 (2): 203-35
31. Rosser R, Kind P. A scale of valuations of states of illness: is there a social consensus? Int J Epidemiol 1978; 7 (4): 347-58
32. EuroQol Group. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 1990; 16 (3): 199-208
33. Essink-Bot ML, Stouthard ME, Bonsel GJ. Generalizability of valuations on health states collected with the EuroQol questionnaire. Health Econ 1993; 2 (3): 237-46
34. Gafni A. Willingness-to-pay as a measure of benefits: relevant questions in the context of public decision making about health care programs. Med Care 1991; 29 (12): 1246-52
35. Labelle RJ, Hurley JE. Implications of basing health-care resource allocations on cost-utility analysis in the presence of externalities. J Health Econ 1992; 11 (3): 259-77
36. Thompson MS. Willingness to pay and accept risks to cure chronic disease. Am J Public Health 1986; 76 (4): 392-6
37. Johannesson M. Economic evaluation of lipid lowering: a feasibility lest of the contingent valuation approach. Health Policy 1992; 20 (3): 309-20
38. Johannesson M. Economic evaluation of hypertension treatment. Int J Technol Assess Health Care 1992; 8 (3): 506-23
39. Feeny D, Barr RD, Furlong W, et al. Quality of life of the treatment process in pediatric oncology: an approach to measurement. In: Osoba D, editor. Effect of cancer on quality of life. Boca Raton (FL): CRC Press, 1991: 73-88
40. Sackett DL, Torrance GW. The utility of different health states as perceived by the general public. J Chronic Dis 1978; 31 (11): 697-704
41. Llewellyn-Thomas HA, Sutherland HJ, Thiel EC. Do patients' evaluations of a future health state change when they actually enter that state? Med Care 1993; 31 (11): 1002-12
42. Williams A. Ethics and efficiency in the provision of health care. In: Bell JM, Mendus S, editors. Philosophy and Medical Welfare. Cambridge: Cambridge University Press, 1988: 111-26
43. Loomes G, McKenzie L. The use of QALYs in health care decision making. Soc Sci Med 1989; 28 (4): 299-308
44. Gafni A, Birch S. Equity considerations in utility-based measures of health outcomes in economic appraisals: an adjustment algorithm. J Health Econ 1991; 10 (3): 329-42
45. Broome J. Utility. Econ Phil 1991; 7 (1): 1-12
46. Broome J. QALYs. J Publ Econ 1993; 50 (2): 149-67
47. Sen A. Utility: ideas and terminology. Econ Phil 1991; 7 (2): 277-83
48. Richardson J. Cost-utility analyses: what should be measured - utility, value or healthy years equivalents? Working Paper No. 9. Fairfield (Victoria, Australia): Public Sector Management Institute, Monash University, 1989
49. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977; 296 (13): 716-21
50. Keeler EB, Cretin S. Discounting of life-saving and other non-monetary effects. Manag Sci 1983; 29 (3): 300-6
51. Parsonage M, Neuburger H. Discounting and health benefits. Health Econ 1992; 1 (1): 71-6
52. Australian Commonwealth Department of Health, Housing and Community Services. Manual of resource items and their associated costs. Canberra: Commonwealth Department, 1992
53. Gafni A, Torrance GW. Risk attitude and time preference in health. Manag Sci 1984; 30 (4): 440-51
54. Lipscomb J. Time preference for health in cost-effectiveness analysis. Med Care 1989; 27 (3 Suppl.): S233-53
55. Krahn M, Gafni A. Discounting in the economic evaluation of health care interventions. Med Care 1993; 31 (5): 403-18
56. Fuchs VR. Time preference and health: an exploratory study. In: Fuchs VR, editor. Economic aspects of health. Chicago: University of Chicago Press, 1982: 93-120
57. Harvey CM. The reasonableness of non-constant discounting. J Publ Econ 1994; 53: 31-51
58. Jenkins GP. The public-sector discount rate for Canada: some further observations. Can Public Policy Analyse Politiques 1981; 7 (3): 399-407
59. Ontario Ministry of Health. Ontario guidelines for economic analysis of pharmaceutical products. Toronto: Ontario Ministry of Health, 1994